Today: 21 May 2026
Browse Category

ASX:BGL 30 January 2026

Stock Market Today

  • Snowline Gold Reports Wider Q1 Loss, Highlights Capital Strategy Challenges
    May 20, 2026, 11:55 PM EDT. Snowline Gold (TSX:SGD) posted a first-quarter 2026 net loss of C$8.49 million, up from C$3.38 million a year ago, with loss per share rising to C$0.05 from C$0.02. The increased loss reflects rising exploration expenses amid no revenue generation, spotlighting spending discipline and future financing needs. With C$100 million in cash and ongoing drilling at the Yukon Rogue Project, the company's near-term outlook depends on successful exploration results. Investors face pressures from widening losses and share price softness, underscoring risks in Snowline's pure exploration play. Valuation estimates vary widely, emphasizing speculative nature tied to project progress and funding conditions. The report advises careful assessment of capital strategy amid evolving market and operational challenges.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop